Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority to UY26341ApriorityCriticalpatent/UY26341A1/en
Publication of UY26341A1publicationCriticalpatent/UY26341A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere a una combinación, tal como una preparación combinada o una composición farmacéutica, su uso y preparación respectivamente, que comprende nateglinida (I) o repaglinida, y cuando menos otro compuesto antidiabético seleccionado a partir del grupo que consiste en derivados de tiazolidinadiona (glitazonas), derivados de sulfonilurea, y metformina, para el uso simultáneo, separado, o en secuencia, en la prevención, demora de progreso, o tratamiento de enfermedades, especialmente desórdenes metabólicos, y en particular diabetes tipo 2, y enfermedades y condiciones asociadas con diabetes.The invention relates to a combination, such as a combined preparation or a pharmaceutical composition, its use and preparation respectively, comprising nateglinide (I) or repaglinide, and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), derivatives of sulfonylurea, and metformin, for simultaneous, separate, or sequential use, in the prevention, delay of progress, or treatment of diseases, especially metabolic disorders, and in particular type 2 diabetes, and diseases and conditions associated with diabetes.
UY26341A2000-09-152000-09-15
METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES.
UY26341A1
(en)
A COMBINATION THAT INCLUDES NATEGLINED AND WHEN AT LEAST ANOTHER ANTI-DIABETIC COMPOUND USED FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR OF A DISEASE OR CONDITION ASSOCIATED WITH DIBETES
Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
Spiro-condensed compounds, gpr40 agonists: pharmaceutical composition comprising one of the compounds; and the use of the compounds in the preparation of medications for the treatment of diabetes, hyperglycemia, impaired fasting glucose tolerance, among others.
SUBSTITUTED HETEROARILY DERIVATIVE COMPOUNDS; METHOD FOR THE PREPARATION OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF PAIN, DEPRESSION, ALZHEIMER'S DISEASE AND HYPERTENSION BETWEEN OTHERS.
1,2,4-oxadiazole benzoic acid compounds, pharmaceutical composition (variants) and their use for treating a disease ameliorated by modulation of premature translation termination or nonsense-mediated mrna decay
Pharmaceutical composition comprising: a) the sglt2 inhibitor 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) -benzyl] -benzene, b ) dppiv linagliptin inhibitor and c) a third antidiabetic agent that is metformin hydrochloride; and its use to treat type 2 diabetes mellitus.